

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort CardioFlow Medtech Corporation

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors (the “**Directors**”) of MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries the “**Group**”) hereby announces that the Company has resolved to grant share options (the “**Options**”) to eligible participants (the “**Grantees**”), to subscribe for up to an aggregate of 10,079,716 ordinary shares of the Company of US\$0.000005 each (the “**Shares**”) in the capital of the Company pursuant to the share option scheme (the “**Share Option Scheme**”) adopted by the Company on March 13, 2020 and amended on March 17, 2022, subject to the acceptance of the Grantees.

Details of the Options are as follows:

Date of Grant:	March 30, 2022 (the “ Date of Grant ”)
Exercise price of the Options granted:	HK\$2.534 per Share, representing the highest of (i) the closing price of HK\$2.43 per Share as stated in the daily quotations sheet issued by The Stock Exchange of Hong Kong Limited (the “ Stock Exchange ”) on the Date of Grant; (ii) the average closing price of HK\$2.534 per Share as stated in the daily quotations sheets issued by the Stock Exchange for the five business days immediately preceding the Date of Grant; and (iii) the nominal value of a Share of US\$0.000005
Number of Options granted:	10,079,716 Options (each Option shall entitle the holder of the Option to subscribe for one Share)
Validity period of the Options:	Ten (10) years from the Date of Grant

Vesting period of the Options:	<p>Among the total Options:</p> <ol style="list-style-type: none"> 1. 6,200,000 Options shall be vested in the following manners: the Options shall be vested in five (5) years, 20% of which shall be vested on each anniversary of the Date of Grant; 2. 2,493,493 Options shall be vested in the following manners: half of the Options shall be vested on March 30, 2025, and the rest shall be vested in tranches on the last trading day of each month during the period from April 2025 to March 2027 (inclusive); and 3. 1,386,223 Options shall be vested on March 30, 2028.
Performance targets:	<p>The vesting of the Options is not subject to any performance targets.</p> <p>The purpose of the Share Option Scheme is to provide incentive or reward to eligible persons for their contribution to, and continuing efforts to promote the interests of, our Group. The number of Options to be granted are based on the work performance and potential contributions of the Grantees and no additional performance target is imposed before the Options are vested to the Grantees. In view of the above, the remuneration committee of the Company (the “Remuneration Committee”) considered the grant of Options aligned with the purpose of the Share Option Scheme to motivate the Grantees and allow them to participate in the growth of the Group’s business.</p>
Clawback mechanism:	<p>The Options granted were subject to the clawback mechanism as set out in the terms of the Share Option Scheme, in particular, the lapse of Options upon cessation of employment of the Grantee and the cancellation of Options at the discretion of the Board.</p>
Financial assistance:	<p>There is no arrangement for the Group to provide any financial assistance to the Grantees to facilitate the purchase of the Shares under the Share Option Scheme.</p>

Among the Grantees, 3,121,708 Options were granted to the Directors, with details as follows:

Name	Position	Number of Options
Chen Guoming	Executive Director	410,300
Zhao Liang	Executive Director	1,105,146
Yan Luying	Executive Director	257,213
Jonathan H. Chou	Independent non-executive Director	449,683
Ding Jiandong	Independent non-executive Director	449,683
Sun Zhixiang	Independent non-executive Director	449,683

In accordance with the Rule 17.04(1) of the Listing Rules, the independent non-executive Directors have approved the grant of the above Options to the Directors and each independent non-executive Director has abstained from voting on the resolution in respect of the grant of Options to himself/herself.

The remaining 6,958,008 Options were granted to employees of the Group.

After the grant of the Options, the number of Shares available for future grant under the mandate of the Share Option Scheme is 225,561,658.

By order of the Board
MicroPort CardioFlow Medtech Corporation
Luo Qiyi
Chairman

Shanghai, PRC, March 30, 2023

As at the date of this announcement, the executive Directors are Mr. Chen Guoming, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Dr. Luo Qiyi, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.